4//SEC Filing
WINSTON ROY 4
Accession 0001209191-22-035234
CIK 0001396814other
Filed
Jun 7, 8:00 PM ET
Accepted
Jun 8, 7:48 PM ET
Size
28.6 KB
Accession
0001209191-22-035234
Insider Transaction Report
Form 4
WINSTON ROY
Chief Clinical Officer
Transactions
- Sale
Common Stock
2022-06-06$61.37/sh−2,099$128,824→ 44,357 total - Sale
Common Stock
2022-06-06$60.55/sh−2,535$153,494→ 48,072 total - Sale
Common Stock
2022-06-06$62.43/sh−1,300$81,159→ 44,472 total - Sale
Common Stock
2022-06-06$63.40/sh−115$7,291→ 44,357 total - Sale
Common Stock
2022-06-06$60.55/sh−3,533$213,923→ 40,824 total - Sale
Common Stock
2022-06-06$61.59/sh−3,650$224,804→ 37,174 total - Sale
Common Stock
2022-06-06$62.48/sh−1,891$118,150→ 35,283 total - Exercise/Conversion
Common Stock
2022-06-06$34.38/sh+6,250$214,844→ 50,607 total - Sale
Common Stock
2022-06-06$61.59/sh−2,300$141,657→ 45,772 total - Sale
Common Stock
2022-06-06$63.69/sh−123$7,834→ 35,160 total - Award
Common Stock
2022-06-08+9,900→ 45,060 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-06-06−6,250→ 0 totalExercise: $34.38Exp: 2028-05-02→ Common Stock (6,250 underlying) - Award
Stock Option (Right to Buy)
2022-06-08+24,800→ 24,800 totalExercise: $59.39Exp: 2032-06-08→ Common Stock (24,800 underlying)
Footnotes (13)
- [F1]Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
- [F10]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.60 to $64.06, inclusive.
- [F11]Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F12]The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.
- [F13]The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
- [F2]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.23 to $61.22, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 3 through 10.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.23 to $62.17, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.23 to $62.78, inclusive.
- [F6]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.29 to $64.14, inclusive.
- [F7]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.220 to $61.215, inclusive.
- [F8]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.22 to $62.18, inclusive.
- [F9]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.200 to $62.935, inclusive.
Documents
Issuer
Pacira BioSciences, Inc.
CIK 0001396814
Entity typeother
Related Parties
1- filerCIK 0001751757
Filing Metadata
- Form type
- 4
- Filed
- Jun 7, 8:00 PM ET
- Accepted
- Jun 8, 7:48 PM ET
- Size
- 28.6 KB